FDA Approves Eribulin Mesylate for Advanced Liposarcoma



The FDA has approved eribulin mesylate for patients with liposarcoma whose cancers are advanced or cannot be removed by surgery and are no longer responding to anthracycline-based chemotherapy.



Source link

Comments are closed.